Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Tolerance and Safety of a Recombinant Anti-PD-1 Monoclonal Antibody HX008 in Patients With Advanced Solid Tumors

NCT04825392 is registered in ClinicalTrials.gov with Taizhou Hanzhong biomedical co. LTD as lead sponsor.

NCT NCT04825392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04825392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Tolerance and Safety of a Recombinant Anti-PD-1 Monoclonal Antibody HX008 in Patients With Advanced Solid Tumors
Lead sponsor
Taizhou Hanzhong biomedical co. LTD
Phase
Phase 1
Overall status
Unknown status
Start date
September 5, 2019
Completion date
December 30, 2021
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor